secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-052053
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus Q1 product revenue up 24% to $38.4M; net loss narrows to $9.7M; ReCePI trial met endpoint
--------------------------------------------------------------------------------

- Q1 product revenue $38.4M (+24% YoY); total revenue $43.4M (+13%).
- Net loss $9.7M ($0.05 EPS) vs $15.6M ($0.09) in Q1 2023; adjusted EBITDA -$2.7M.
- ReCePI Phase 3 trial for INTERCEPT Red Blood Cells met primary endpoint in cardiovascular surgery.
- FDA approved 12-month shelf life for INTERCEPT Platelet Processing Sets.
- FY2024 product revenue guidance reaffirmed at $172-175M; IFC guidance $8-10M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000095017024052053/0000950170-24-052053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000095017024052053/cers-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer